News | March 16, 2026
Zuellig Pharma expands Cialis footprint across Asia
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
The expanded ownership is expected to improve access to Cialis for millions of men in Asia affected by ED and BPH
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
